Patents Assigned to PHARMAXIS LTD.
-
Publication number: 20230349907Abstract: The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.Type: ApplicationFiled: February 5, 2021Publication date: November 2, 2023Applicant: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Heidi Schilter Sambade, Wenbin Zhou, Lara Anne Perryman
-
Publication number: 20220251036Abstract: The present invention relates to methods for preparing a variety of difluorohaloallylamine derivatives. The present invention also relates to novel difluorohaloallylamine derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer and/or scarring in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as uses thereof.Type: ApplicationFiled: July 24, 2020Publication date: August 11, 2022Applicant: PHARMAXIS LTD.Inventors: Dieter Wolfgang HAMPRECHT, Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Angelique Elsa GRECO, Wolfgang JAROLIMEK, Wenbin ZHOU
-
Patent number: 11098045Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: June 11, 2020Date of Patent: August 24, 2021Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20200317666Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: June 11, 2020Publication date: October 8, 2020Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10786637Abstract: A delivery device is provided having a container containing a dose of greater than 40 mg of a powder and having at least one exit orifice for dispensing the dose from the container, a chamber adapted to receive the container in an operative configuration, at least one gas inlet by which gas may enter the chamber and at least one gas outlet by which gas and entrained powder may exit the chamber. The delivery device is operable to generate a gas flow through the chamber between the at least one gas inlet and the at least one gas outlet, which brings about orbital motion of the container within the chamber in that at least a central region of the container orbits a central axis of the chamber.Type: GrantFiled: July 13, 2012Date of Patent: September 29, 2020Assignee: Pharmaxis Ltd.Inventors: Philip Seeney, Douglas Ivan Jennings
-
Patent number: 10717733Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: February 10, 2017Date of Patent: July 21, 2020Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10717734Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: February 10, 2017Date of Patent: July 21, 2020Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20190119269Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: February 10, 2017Publication date: April 25, 2019Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10220164Abstract: A delivery device is provided which has a container containing a dose of a powder, a chamber adapted to receive the container, at least one gas inlet by which gas may enter the chamber, and at least one gas outlet by which gas and entrained powder may exit the chamber for inhalation. The delivery device has a pre-use configuration in which the container is accommodated, at least partially, within a storage enclosure in a wall of the chamber. The delivery device has a deployment member adapted to put the delivery device in an operative configuration by displacing the container from the storage enclosure into the chamber, such that the container is movable within the chamber, in use, the deployment member being adapted to at least partially occupy the storage enclosure in the operative configuration.Type: GrantFiled: July 13, 2012Date of Patent: March 5, 2019Assignee: Pharmaxis Ltd.Inventors: Philip Seeney, Douglas Ivan Jennings
-
Publication number: 20190040007Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: February 10, 2017Publication date: February 7, 2019Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 9795748Abstract: A delivery device is provided which comprises a container containing a dose of a powder and having at least one exit orifice for dispensing the dose from the container and a chamber adapted to receive the container in an operative configuration. The device further comprises at least one gas inlet by which gas may enter the chamber and at least one gas outlet by which gas and entrained powder may exit the chamber. The delivery device is operable to generate a gas flow through the chamber between the at least one gas inlet and the at least one gas outlet, which brings about orbital motion of the container within the chamber in that at least a central region of the container orbits a central axis of the chamber. The volume occupied by the container is at least 25% of the volume of the chamber.Type: GrantFiled: July 13, 2012Date of Patent: October 24, 2017Assignee: Pharmaxis Ltd.Inventors: Philip Seeney, Douglas Ivan Jennings
-
Publication number: 20140174441Abstract: A delivery device is provided which has a container containing a dose of a powder, a chamber adapted to receive the container, at least one gas inlet by which gas may enter the chamber, and at least one gas outlet by which gas and entrained powder may exit the chamber for inhalation. The delivery device has a pre-use configuration in which the container is accommodated, at least partially, within a storage enclosure in a wall of the chamber. The delivery device has a deployment member adapted to put the delivery device in an operative configuration by displacing the container from the storage enclosure into the chamber, such that the container is movable within the chamber, in use, the deployment member being adapted to at least partially occupy the storage enclosure in the operative configuration.Type: ApplicationFiled: July 13, 2012Publication date: June 26, 2014Applicant: PHARMAXIS LTD.Inventors: Philip Seeney, Douglas Ivan Jennings
-
Publication number: 20140163085Abstract: There is provided herein, an oligonucleotide directed against a target gene, wherein the oligonucleotide is capable of hybridizing to at least a portion of a nucleic acid sequence encoding the gene under stringent conditions, and wherein, at least one nucleotide of the oligonucleotide is 2-amino-2?-deoxyadenosine (DAP); and the internucleoside linkages of the oligonucleotide comprises at least three alternating segments, each segment consisting of either at least one phosphorothioate or at least one phosphodiester bond.Type: ApplicationFiled: February 23, 2012Publication date: June 12, 2014Applicant: PHARMAXIS LTDInventors: Rosanne Seguin, Nicolay Ferrari
-
Publication number: 20140137865Abstract: A delivery device is provided which comprises a container containing a dose of a powder and having at least one exit orifice for dispensing the dose from the container and a chamber adapted to receive the container in an operative configuration. The device further comprises at least one gas inlet by which gas may enter the chamber and at least one gas outlet by which gas and entrained powder may exit the chamber. The delivery device is operable to generate a gas flow through the chamber between the at least one gas inlet and the at least one gas outlet, which brings about orbital motion of the container within the chamber in that at least a central region of the container orbits a central axis of the chamber. The volume occupied by the container is at least 25% of the volume of the chamber.Type: ApplicationFiled: July 13, 2012Publication date: May 22, 2014Applicant: PHARMAXIS LTD.Inventors: Philip Seeney, Douglas Ivan Jennings
-
Publication number: 20140130800Abstract: A delivery device is provided having a container containing a dose of greater than 40 mg of a powder and having at least one exit orifice for dispensing the dose from the container, a chamber adapted to receive the container in an operative configuration, at least one gas inlet by which gas may enter the chamber and at least one gas outlet by which gas and entrained powder may exit the chamber. The delivery device is operable to generate a gas flow through the chamber between the at least one gas inlet and the at least one gas outlet, which brings about orbital motion of the container within the chamber in that at least a central region of the container orbits a central axis of the chamber.Type: ApplicationFiled: July 13, 2012Publication date: May 15, 2014Applicant: PHARMAXIS LTD.Inventors: Philip Seeney, Douglas Ivan Jennings
-
Patent number: 8426587Abstract: The present invention is related to the preparation and pharmaceutical use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: (I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.Type: GrantFiled: November 19, 2008Date of Patent: April 23, 2013Assignee: Pharmaxis Ltd.Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot
-
Publication number: 20100298330Abstract: The present invention is related to the preparation and pharmaceutical In use of novel haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification:(I). The invention also relates to methods of using invention compounds, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases.Type: ApplicationFiled: November 19, 2008Publication date: November 25, 2010Applicant: PHARMAXIS LTD.Inventors: Ian A. McDonald, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot